Published in Clin Exp Immunol on July 01, 2006
Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04
A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward? PLoS Negl Trop Dis (2014) 0.84
CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis. Clin Exp Immunol (2008) 0.82
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity (2016) 0.81
Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30. Infect Agent Cancer (2010) 0.81
Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol (2009) 0.79
Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob Agents Chemother (2014) 0.75
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature (2002) 11.79
The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 3.63
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol (2001) 3.21
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J (1995) 2.23
Th1 and Th2 in human diseases. Clin Immunol Immunopathol (1996) 2.08
Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90
Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clin Immunol Immunopathol (1990) 1.71
Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol Rev (2004) 1.59
Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis (1998) 1.49
Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest (1993) 1.47
An endemic focus of visceral leishmaniasis in Meshkin-Shahr, east Azerbaijan province, north-west part of Iran and IFA serological survey of the disease in this area. Bull Soc Pathol Exot Filiales (1988) 1.45
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol (1998) 1.40
In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine (1995) 1.13
Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology (1999) 1.12
Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol (2000) 1.05
Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol (1997) 1.03
CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-gamma. Lab Invest (1995) 0.99
Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells. Infect Immun (1999) 0.99
Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol (2002) 0.92
Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol (1996) 0.92
Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol (2004) 0.91
Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine (2000) 0.90
Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol (2000) 0.85
T-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (sCD30). Arch Dermatol Res (1997) 0.80
Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity? Cytokine (2000) 0.80
Epidemiologic study of visceral leishmaniasis in Honduras, 1975-1983. Am J Trop Med Hyg (1985) 0.79
Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient. J Microbiol Immunol Infect (2004) 0.77
Distinct strains of Leishmania major induce different cytokine mRNA expression in draining lymph node of BALB/c mice. Parasite Immunol (2013) 0.81
Cloning, Expression and Characterization of Zebra Fish Ferroportin in Hek 293T Cell Line. Iran J Public Health (2012) 0.75
Hydrogel nanoparticle encapsulated plasmid as a suitable gene delivery system. Tsitol Genet (2015) 0.75